Yu-I Li1, Ji-Shiang Hung2, Tse-Ya Yu3, Jyh-Ming Liou4, Jung-Nan Wei5, Hsien-Li Kao4, Lee-Ming Chuang6, Chia-Tung Shun1, Po-Huang Lee7, Hong-Shiee Lai7, Chien-Yin Su4, Hung-Yuan Li4, Jin-Tung Liang7. 1. Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, Medical College, National Taiwan University, Taipei, Taiwan. 3. Department of Internal Medicine, En Chu Kong Hospital, New Taipei City, Taiwan. 4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 5. Chia Nan University of Pharmacy and Science, Tainan, Taiwan. 6. Graduate Institute of Clinical Medicine, Medical College, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 7. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 can predict cancer mortality, including colorectal cancer (CRC) mortality, in type 2 diabetic subjects. However, it remains unknown if serum VAP-1 can predict mortality in CRC patients. This prospective cohort study investigates if serum VAP-1 is a novel biomarker for mortality prediction in CRC. METHODS: We enrolled 300 CRC patients. Preoperative serum VAP-1 was measured by time-resolved immunofluorometric assay. They were followed until September 2009 or death, which was ascertained by the National Death Registration System. RESULTS: The median follow-up period was 4.7 years. Compared with normal counterpart, VAP-1 immunoactivity was upregulated in CRC tissues, especially at the invasion front. Serum VAP-1 can independently predict all-cause mortality (HR: 1.0026, 95% CI: 1.0003-1.0050, P<0.05) and cancer-related mortality (HR: 1.0026, 95% CI: 1.0001-1.0050, P<0.05). A risk score composed of age, gender, carcinoembryonic antigen (CEA) >5 ng/ml, tumor grading, tumor staging, and serum VAP-1 could stratify CRC patients into low-, intermediate-, and high-risk subgroups, with a 5-year mortality rate of 10%, 34%, and 78%, respectively. CONCLUSIONS: Serum VAP-1 predicts mortality independently and improves risk stratification in CRC subjects.
BACKGROUND:Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 can predict cancer mortality, including colorectal cancer (CRC) mortality, in type 2 diabetic subjects. However, it remains unknown if serum VAP-1 can predict mortality in CRC patients. This prospective cohort study investigates if serum VAP-1 is a novel biomarker for mortality prediction in CRC. METHODS: We enrolled 300 CRC patients. Preoperative serum VAP-1 was measured by time-resolved immunofluorometric assay. They were followed until September 2009 or death, which was ascertained by the National Death Registration System. RESULTS: The median follow-up period was 4.7 years. Compared with normal counterpart, VAP-1 immunoactivity was upregulated in CRC tissues, especially at the invasion front. Serum VAP-1 can independently predict all-cause mortality (HR: 1.0026, 95% CI: 1.0003-1.0050, P<0.05) and cancer-related mortality (HR: 1.0026, 95% CI: 1.0001-1.0050, P<0.05). A risk score composed of age, gender, carcinoembryonic antigen (CEA) >5 ng/ml, tumor grading, tumor staging, and serum VAP-1 could stratify CRC patients into low-, intermediate-, and high-risk subgroups, with a 5-year mortality rate of 10%, 34%, and 78%, respectively. CONCLUSIONS: Serum VAP-1 predicts mortality independently and improves risk stratification in CRC subjects.
Authors: Stephen T Ward; Christopher J Weston; Emma L Shepherd; Rahul Hejmadi; Tariq Ismail; David H Adams Journal: BMC Cancer Date: 2016-02-24 Impact factor: 4.430